possible that this kinase contributes to the disease [8, 9] .
Isoforms of CaMK II are encoded as single polypeptides each containing a catalytic, a regulatory, a variable and an association domain with molecular masses between 50 000 and 60 000 M r . The catalytic domain has features similar to most serine threonine protein kinases. The kinase domain is located in the N-terminal half of the molecule followed by a regulatory domain which is the site of calmodulin binding and autophosphorylation, through which CaMK II can sustain its own activity after a Ca 2+ surge [10±14] . The regulatory domain is followed by a region of high variability where most differences between the 4 CaMK II genes are found. In this region extensive splicing occurs generating between 2 and 12 subtypes of each isoform [15±18] . The precise role of this region is not known but it is thought it enables the protein to associate with subcellular organelles and cytoskeletal structures [19] . The C-terminal part of the enzyme is responsible for oligomerisation of CaMK II allowing for the association of 6 to 12 subunits [1, 20] . Cells can contain more than a single isoform of the kinase and both, homomultimers and heteromultimers, of the kinase can exist.
It has been proposed that CaMK II participates in the regulation of insulin secretion from beta cells [5, 6, 21, 22] . Glucose was shown to activate CaMK II in beta cells and to cause its autophosphorylation [23] . An antagonist of CaMK II, KN-62, was shown to inhibit insulin secretion [24, 25] but also to inhibit voltage-regulated Ca 2+ channels which can, by itself, prevent insulin secretion [26] . Studies at the single cell level have shown the inhibition of insulin exocytosis in response to glucose on treatment of beta cells with a peptide inhibitory to CaMK II [27, 28] . Indeed, CaMK II has been localised on insulin granules both in fish [21] and rat islets and in INS-1 cells [29] . Further studies have confirmed an association with insulin granules and have proposed synapsin 1 and microtubule-associated protein (MAP)-2 as important substrates [30±32] . In INS-1 cells suppression of CaMK II caused a decreased mRNA expression of insulin, glucokinase and GLUT-2 suggesting that CaMK II not only has a role in exocytosis but also in the regulation of gene expression of molecules which are involved in glucose-stimulated insulin secretion. This was confirmed by western blot analysis and colorimetric measurement of glucose metabolism [33, 34] .
Partial human sequences of CaMK IIa, b and d have been identified as sequence tagged sites in a shotgun approach of random cDNA sequencing [35] . The human CaMK IIg and several splice variants thereof were previously cloned from a lymphocyte cDNA library [15] .
Very recently while this work was in progress another study [36] used a PCR approach to amplify the variable region of all subtypes of CaMK II from several human tumour cell types and identified two splice variants of CaMK IIb, four of CaMK IIg and two of CaMK IId.
The aim of this study was (1) to identify the isoforms of CaMK II present in human beta cells, (2) to obtain their complete cDNA sequences, (3) to determine quantitatively their contribution to CaMK II types in beta cells and (4) to obtain an idea of their expression in other tissues to define them as either largely beta-cell specific or widely expressed molecules. The latter could be of relevance when searching for associations between single nucleotide polymorphisms of CaMK II isoforms and human diseases such as Type II diabetes.
Methods
Materials. We obtained Taq DNA polymerase and primers for PCR from Gibco, Gaithersburg, Md., USA, or MWG Biotech, Munich, Germany, reverse transcriptase M-MuLV-RT and random primers pd(N) 6 from Boehringer, Mannheim, Germany, RNasin and dNTPs from Promega, Madison, Wis., USA, the ABI-PRISM Dye Terminator cycle sequencing kit from Applied Biosystems, Foster City, Calif., USA and Polymorphprep from Nycomed, Oslo, Norway. Restriction endonucleases and T4 ligase were from Boehringer, Mannheim. Chemicals were purchased from Merck, Darmstadt, Germany, except where indicated otherwise.
Molecular cloning of human CaMK II cDNA. The human insulinoma cDNA library in a l-gt11 vector was prepared as described previously [37] . Inserts of plaque-purified clones were released by EcoRI-digest and subcloned into pBluescript KS with or without phagemid (Stratagene, La Jolla, Calif., USA) using T4 ligase. Sequencing was done on a Perkin Elmer sequencer (Foster City, Calif., USA) using the ABI-PRISM Dye Terminator cycle sequencing mix.
Tissue and cell preparation. Human adipose tissue and muscle were obtained from patients undergoing hip surgery. Pituitary tissue was from hypophysectomy of non-functioning pituitary adenomas. Patients gave their informed consent and an ethical committee approved the study. Bone cells were cultured from primary bone explants as described [38] and consisted of passage 2 osteoblasts. Bone cells were grown in Hams F12K medium (Seromed, Berlin, Germany) containing 10 % fetal calf serum (Gibco). Fibroblasts were cultured from non-transformed tissue explants obtained from patients undergoing surgery for colon carcinomas using DMEM medium (Gibco) supplemented with 10 % fetal calf serum. Normal adrenal cortex tissue was obtained during bilateral adrenalectomy from patients operated because of ectopic ACTH syndrome. A second sample was obtained from normal adrenal cortex during adrenalectomy because of a pheochromocytoma. Liver tissue was obtained from a control biopsy during cholecystectomy which showed histologically normal liver tissue. Human beta cells were isolated from three patients by fluorescence-activated cell sorting as described previously [39] .
Mononuclear leucocytes were obtained by density gradient centrifugation of whole blood using Polymorphprep as described in the user manual. Thrombocytes were obtained by centrifugation of EDTA blood for 10 min at 350´g followed by a second centrifugation of the supernatant for 10 min at 800´g. Thrombocytes, mononuclear leucocytes, osteoblasts and pituitary adenomas were homogenised by ultrasound, other tissues by an Ultra Turrax homogeniser (Janke and Kunkel, Staufen, Germany).
RNA isolation and reverse transcription. Total RNA from tissues was isolated by the acid guanidinium thiocyanate method [40] . Total RNA was quantified by determination of the O. D. at 260 and 280 nm. Reverse transcription (RT) was done by using 0.5±1 mg of total RNA and the following additions (final concentration): 20 U RNasin, 40 pmol (0.5 mg) random primer pd(N) 6 , 20 pmol dNTP, reaction buffer as supplied, ultrapure H 2 O to a total volume of 20 ml. The reaction mix was heated to 65°C for 5 min and cooled to 25°C for 10 min to allow random primers to anneal. We added 20 units of M-MuLV-RT for 60 min at 37°C. The reaction was stopped by denaturing at 95°C for 5 min.
Polymerase chain reaction. All primers were created with Primer Designer 2.0 (Scientific & Educational Software 1991, Durham, N. C., USA). We mixed 10 to 200 ng of reverse transcribed total RNA with the following additions to a final volume of 100 ml (final concentrations): 1.5±3 mmol/l MgCl 2 , 20 pmol dNTP, 30 pmol of upstream and downstream primer and 2 U of Taq-DNA-polymerase, reaction buffer as supplied and ultrapure water. The PCR was started by denaturing for 2 min at 95°C followed by up to 45 cycles of 40 s at 95°C, 30 s at the specific annealing temperature, 1 min at 72°C. Final elongation was done for 10 min at 72°C. We then analysed 8 to 16 ml of the PCR reaction on a 2 % agarose gel by submarine electrophoresis at 5 V/cm. Detection was done with ethidium bromide staining.
Sequencing of PCR products. Polymerase chain reactions, which showed a single band were sequenced after purification by the High Pure PCR Product Purification Kit from Boehringer. If there were two or more bands in a PCR reaction, the single bands were excised from the agarose gel and prepared by the High Pure PCR Product Purification Kit. The purified amplificates were sequenced twice with the ABI-PRISM Dye Terminator cycle sequencing mix and either the 5 ¢-primer or 3 ¢-primer and then analysed on a Perkin Elmer sequencer. Expected bands were sequenced at least once for confirmation, new bands were sequenced three times.
Semiquantitative comparative PCR with internal cDNA standards. For use as internal standards, primers were designed for pyruvate dehydrogenase (PDH) (E. C.1.2.4.1) b-subunit sequence (NID g219983/GenBank) ( Table 1 ). These primers were used for amplification together with the target CaMK II primer. At the end of cycle number 21, 24, 27, 30, 33, 36, 39, 42 and 45 the entire reaction was cooled on ice for 1 min and 8 ml were removed for analysis by submarine gel electrophoresis. The linearity of the amplifications was controlled by densitometric scanning of the gels and plotting of the density against the cycle number. The amplifications were analysed in the linear range as described in detail previously [41] . Shortened standard fragments of these sequences were generated by deleting 50 to 80 bp of internal sequence. The standards contained the same sequences within the primer binding region and the remaining internal cDNA sequence. These standards were added at different concentrations to the PCR mix and comparative PCR was done at each concentration. The concentration at which the shortened standard was amplified similarly to the target sequence was taken as indicating similar concentrations of standard and target cDNA. The use of comparative PCR at each quantity of competitive standard assured that similar amplification was obtained over a wide range of cycles thus avoiding a potential source of error in competitive PCR.
Results
To identify subtypes of CaMK II expressed in insulinproducing cells a human insulinoma l-gt11 cDNA library was screened. The complete coding sequence of rat CaMK IId 2 was used as a probe because this type of CaMK II was the major isoform in rat islets and in INS-1 and RINm5F rat insulinoma cells [29] . A screen at intermediate stringency (42°C hybridisation temperature) allowed the identification of ten positive clones which were subcloned and sequenced. Of the ten, seven clones were 92 % homologous to the rat CaMK IIb cDNA sequence (Fig. 1A) , two were 93 % homologous to rat CaMK IId cDNA (Fig. 2) and one corresponded to the known sequence of human CaMK IIg [43] . The clones representing CaMK IIb contained a complete coding sequence of 1509 bp encoding for 503 amino acids (EMBL Accession No. AJ252 236). This molecule, termed human CaMK IIb 1 differed from the rat subtype b by the absence of the sequence in the first and the third variable domain termed V1 and V3 (Fig. 1B,C) [44] . Furthermore we found a second coding sequence of 1437 bp, which had the same nucleotide sequence as the subtype b 1 but had a 72 bp deletion at position 988 (EMBL AJ252 237). This subtype, termed b 2 , had deletions of all three variable domains V1 to V3 (Fig. 1B,C ).
An alignment of the amino acid sequences of the rat and human CaMK IIb that were deduced showed an extreme degree of sequence conservation. There was only one amino acid difference outside the variable domains which was C-terminal in the association domain. There was no difference in amino acid sequence of the complete catalytic and regulatory domains from amino acids 1±315. The six other variations were within the variable domains and four of those within the differently spliced fragments (Fig. 1C) .
The clones representing CaMK IId contained the previously unknown 727 bp of the 5 ¢-region including the translational start codon and the kinase domain of the enzyme (EMBL AJ252 239). The human nucleotide sequence was 93 % homologous ( Fig. 2) and the amino acid sequence deduced was 100 % identical to that of the rat. Additionally 427 bp of the 5 ¢ untranslated sequence were cloned (Fig. 2) .
To obtain an idea whether human CaMK IIb is preferentially expressed in the central nervous system as shown in rats, we searched for CaMK IIb subtypes which might occur in peripheral tissues. To allow scanning of the entire coding sequence five pairs of primers were designed for amplification of overlapping fragments. Screening of different human tissues showed an additional subtype of CaMK IIb which had an insertion of 45 bp, which corresponds to the V 3 region, immediately following the V 2 region which differed between subtype b 1 and b 2 . This subtype termed CaMK IIb 4 had 1552 bp and was coding for 518 amino acids (EMBL AJ252 238) (Fig. 1B,D) . All human tissues and cell lines we investigated contained the subtypes b 1 and b 2 . We also detected CaMK IIb 4 in all tissues except for a pheochromocytoma. We were not able to identify a human CaMK IIb 3 in any of the primary human tissues investigated [45] .
The CaMK IIb isoform was extremely difficult to amplify from leucocytes due to very low expressions of the mRNA. A correct amplification of the complete coding sequence was only obtained in 10 out of 30 cDNA samples of human mononuclear cells investigated. Low expression was found in fat and muscle tissue, primary fibroblasts and in primary osteoblast cultures [38] . We additionally tested endocrine tissues and found a strong expression of CaMK IIb in adrenal cortex, pheochromocytomas and pituitary. To obtain a measure of CaMK IIb gene expression the number of cycles of PCR needed to obtain a detectable positive signal relative to the signal of the housekeeping enzyme pyruvate dehydrogenase (comparative PCR) was determined. In beta cells, pituitary and a pheochromocytoma a positive signal was ob- tained at the same cycle number as PDH whereas in leucocytes at least 10 additional cycles were needed to detect a CaMK II b-cDNA signal (Fig. 3) . This indicates an about 2 10 -fold ( = 1024) difference in gene expression between these tissues. The highest expression relative to PDH of CaMK IIb was seen in cDNA obtained from purified human beta cells (Fig. 3) . Moderate expressions were observed in liver (Fig. 3) .
We were particularly interested in investigating the isoforms of CaMK II present in human beta cells where CaMK II is a possible candidate gene for Type II diabetes. The isoforms present in beta cells were determined because a precise knowledge of the isoforms and relative quantities of the CaMK II subtypes should be helpful in deciding which isoform of this enzyme should be considered as a candidate gene for causing Type II diabetes. Primers for detection of human CaMK IIa, b, g and d were designed and used in RT-PCR of the human beta-cell RNA. Human beta cells expressed CaMK IIg-mRNA and d-mRNA in addition to CaMK IIb. We did not, on the contrary, find CaMK IIa, but a positive control for the successful amplification of human CaMK IIa was obtained in pheochromocytoma cDNA (data not shown). We identified the subtypes b 1 , b 2 and b 4 of CaMK IIb but could not find a PCR product corresponding to the subtype b 3 [45] . The b 1 signal greatly exceeded, however, that of the other isoforms.
In view of the importance of CaMK II in human beta cells it was of interest to obtain information on the quantitative expression of the isoforms. Internal standards were designed for CaMK IIb, g and d and additionally for PDH. Competitive quantitative PCR was carried out using the same amount of betacell cDNA in the presence of different internal standard concentrations. On the resulting gels the intensity of the CaMK II amplificates (upper bands) and the standard amplificates (lower bands) were compared. For CaM kinase II b the competition phenomenon was detected between 10 and 50 fg of internal standard DNA, for CaM kinase II g at 1 fg, for CaM kinase II d and PDH between 50 and 100 fg (Fig. 4) . Altogether nine experiments of competitive quantitative PCR with RNA from three subjects were done. In these experiments the average amount of mRNA in human beta cells (means ± SEM) equalled 47.9 fg + 7.86 SEM of CaMK IIb, 41.3 fg + 1.33 SEM of CaMK IId, 2.4 fg + 0.56 SEM of CaMK IIg and 138.9 fg + 30.9 SEM of the PDH standard DNA. This agrees very well with the results obtained in semiquantitative comparative PCR for CaMK IIb as described above (Fig. 3) and shows that the mRNAs coding for CaMK IIb and d have a high abundance equalling the mRNA of PDH in beta cells.
Discussion
We report the complete human cDNA sequence of CaMK IIb. Remarkably the human CaMK II se- There was no difference within the first 316 amino acids comprising the entire kinase and regulatory domains. The differences between rat and human concerned the presence or absence of the variable domains. The V 1 -region [43, 44] was absent in all three human b-subtypes identified. The variations between the 3 b-subtypes described here all occurred in the V 2 -region and V 3 -region. The b 1 -subtype has deleted V 1 -domains and V 3 -domains. The b 2 -subtype, which has not previously been detected in other species, lacked all variable regions (V 1 ±V 3 ). This is rather unusual for most CaMK II subtypes and was previously observed only in the d 2 subtype.
A third subtype was detected by RT-PCR which only lacked the V 1 -region compared with the rat brain subtypes and was termed b 4 to avoid confusion with the b 3 -subtype described before [17, 45] .
We were unable to find the b 3 isoform in human tissue. Another study described a complete nucleotide sequence identity of the rat and human b 3 insertion [45] . This is unusual as we and others [15] observed about 8 % and higher variations between rats and humans at the nucleotide level, which was evenly distributed over the entire sequence. The b 3 isoform also was not identified by others [36] who analysed the human CaMK II variable region by PCR. Because the b 3 -isoform contains a relatively long insert it could be difficult, however, to amplify by PCR, particularly in the presence of larger quantities of CaMK IIb 1 due to competition.
The clone representing the human sequence of CaMK IId comprised the kinase domain and showed 93 % identity at the nucleotide and 100 % at the amino acid levels between the rat and the human sequence again showing an extreme degree of sequence conservation. A partial sequence of CaMK IId was previously reported to be widely expressed in human tissues [36] as shown by PCR analysis of its regulatory domain and has been found in all cell types examined until now.
The distribution of CaMK IIb differed quite considerably between humans and rats where the enzyme is largely confined to the central nervous system and is not expressed in the periphery [3] . In humans the CaMK IIb sequence was detectable by PCR in numerous cell types but the expression differed widely.
The determination of CaMK II expression by PCR only does not permit an estimation of relative and absolute expression. For this reason two different methods of quantitative PCR [42] were used, because the semiquantitative (comparative) PCR offers the ability to determine the expression of CaM kinases by comparison with the expression of a reference gene whereas absolute concentrations of amplified cDNA can be quantified by competitive PCR. In this study the pyruvate dehydrogenase was chosen as a reference gene because it is present in most tissues and thought to have a key regulatory role in glucose metabolism and aerobic energy production (housekeeping enzyme). The state of activation of PDH was shown to be increased by high glucose concentrations in beta cells and vice versa [46] and in adipose tissues a correlation of PDH activity and expression was ob- served [47] , indicating a direct influence of carbohydrates on the protein content of PDH.
When compared with PDH very low expression of CaMK IIb was found in leucocytes where the mRNA was only marginally detectable. Fibroblasts, osteoblasts and tissues such as striated muscle and fat had low expression. In contrast, high expression of mRNA was found in two types of tissue: endocrine cells such as pituitary, adrenal glands and beta cells and, although to a lesser extend, in liver tissue.
In this context it is notable that some genes share high expression in beta cells and the liver and are involved in metabolic regulation such as GLUT1/2 and glucokinase [48] . The high abundance of CaM kinase IIb and d mRNA could lead to the conclusion that these isoforms are important molecules in beta-cell physiology, compared with CaM kinase IIg, but this has to be proven.
At this time the exact role of CaMK II in glucosestimulated insulin release is not clear. In mammalian brain, CaMK IIb is highly expressed in synapses where it accounts for about 2 % of the cellular protein [49] . A function in neurotransmitter exocytosis seems probable but its precise function is not known. It seems CaMK IIb forms heterooligomers with CaMK IIa in the brain and could account for the binding of the complex to cytoskeletal and synaptic structures. A similar function can be presumed for CaMK IIb/d in beta cells. In the insulinoma cell lines INS-1 and RINm5F, CaMK IId is predominantly associated with insulin granules and attached cytoskeletal structures [29] . In clonal beta cells, synapsin I and microtubule-associated protein (MAP)-2 are substrates which are phosphorylated by CaMK II [31] and which could be related to its effects on insulin secretion [50] .
Another possible role of CaMK II is the regulation of gene expression in beta cells.
Antisense suppression of CaMK IId gene expression in INS-1 cells resulted in the loss of glucokinase, GLUT-2 and insulin gene expression, indicating that CaMK II participates in the regulation of these genes [33] .
In humans, the mRNAs of the CaMK IIb and dsubtypes are highly expressed in beta cells and represent the major isoforms.
